Idiopathic granulomatous mastitis (IGM) is a benign chronic inflammatory breast disease of unknown etiology. No consensus exists as to the best therapeutic approach, though treatment choices include antibiotics, drainage, surgical excision, steroids, methotrexate, and observation. Herein we report a case of idiopathic granulomatous mastitis that was refractory to methotrexate and intralesional and systemic steroids but responded well to mycophenolate mofetil 1500mg twice daily. To our knowledge, this is the first report of the effective use of mycophenolate mofetil in idiopathic granulomatous mastitis.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2eDNSpA
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Predictive Success Factors in Selective Upper Airway Stimulation. ORL J Otorhinolaryngol Relat Spec. 2017 Feb 24;79(1-2):121-128 Auth...
-
Abstract Background The introduction of aggressive chemo-radiotherapy regimens has improved overall survival in children with primitive ...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
Abstract Desmoplastic small round cell tumor (DSCRT) is a rare malignancy most often seen in the abdomen or pelvis of young men. Unfortuna...
-
Abstract Nonmotor symptoms (NMS) have been described in several neurodegenerative diseases but have not been systematically evaluated in sp...
-
Article content meets expectations Minimal relevance to assigned subject matter. Article content fails to meet all requirements Not Rubric f...
-
Objective To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by 68 Ga DO...
-
Elementary school kids, on the other hand, can read, write, reason and think highly complex thoughts. Adele Faber and Elaine Mazlish, author...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου